Skip to main content
Clinical Trials/NCT01063361
NCT01063361
Completed
Phase 2

Effect of Low Glycemic Index Diets (With Pulses) on Glucose Control in Non-Insulin Dependent Diabetics

University of Toronto1 site in 1 country131 target enrollmentFebruary 2010
ConditionsType 2 Diabetes

Overview

Phase
Phase 2
Intervention
Not specified
Conditions
Type 2 Diabetes
Sponsor
University of Toronto
Enrollment
131
Locations
1
Primary Endpoint
change in HbA1c
Status
Completed
Last Updated
10 years ago

Overview

Brief Summary

Healthy individuals with type 2 diabetes will receive intensive counseling on food selection to improve glucose control using either high cereal fiber dietary strategies or low glycemic index foods emphasizing dried legumes and their products. The treatments will last 3 months with bloods taken for HbA1c, glucose and blood lipids. If the study shows a benefit for either or both diets, then use of high fiber and/or low glycemic index foods in the diet may provide another potential way to improve glucose control and lower cholesterol levels in non-insulin dependent diabetes.

Registry
clinicaltrials.gov
Start Date
February 2010
End Date
August 2015
Last Updated
10 years ago
Study Type
Interventional
Study Design
Parallel
Sex
All

Investigators

Responsible Party
Principal Investigator
Principal Investigator

David Jenkins

Principle Investigator

University of Toronto

Eligibility Criteria

Inclusion Criteria

  • Men and women with type 2 diabetes who
  • are treated with oral hypoglycemic agents at a stable dose for at least 8 weeks
  • have a HbA1c in the range of 6.5% to 8.5% at screening and at the visit prior to randomization
  • have diabetes diagnosed \>6 months
  • have maintained stable weight for 2 months (within 3%)
  • have a valid OHIP card and a family physician
  • if prescribed lipid medication, have taken a stable dose for at least 2 weeks
  • if prescribed blood pressure medication, have taken a stable dose for at least 1 week
  • can keep written food records, with the use of a digital scale

Exclusion Criteria

  • Individuals who
  • take insulin
  • take steroids
  • have GI disease (gastroparesis, celiac disease, ulcerative colitis, Crohn's Disease, IBS)
  • have had a major cardiovascular event (stroke or myocardial infarction) in the past 6 months
  • take warfarin (Coumadin)
  • have had major surgery in the past 6 months
  • have a major debilitating disorder
  • have clinically significant liver disease (AST or ALT \> 130 U/L), excluding NAFL or NASH
  • have hepatitis B or C

Outcomes

Primary Outcomes

change in HbA1c

Time Frame: from prestudy and week 0, to end of treatment weeks 8, 10, and 12

serum lipids

Time Frame: from prestudy and week 0, to end of treatment weeks 8, 10, and 12

Secondary Outcomes

  • creatine, urea, and c-peptides in 24 hour urine collection(0, 12 weeks.)
  • change in weight, waist and hip circumference(weeks 0, 12)
  • fasting glucose(from prestudy and week 0, to end of treatment weeks 8, 10, and 12)
  • blood pressure(from prestudy and week 0, to end of treatment weeks 8, 10, and 12)

Study Sites (1)

Loading locations...

Similar Trials